Literature DB >> 21183355

Synthesis and evaluation of β-carboline derivatives as potential monoamine oxidase inhibitors.

J Reniers1, S Robert, R Frederick, B Masereel, S Vincent, J Wouters.   

Abstract

Previous studies have shown that harmine is a reversible inhibitor of human monoamine oxidase A (MAO-A). Moreover, the crystal structure of human MAO-A in complex with harmine has been recently solved. This crystal structure shows that close to the methoxy group of the harmine moiety, a lipophilic pocket is left vacant within the binding site of human MAO-A. Our objective was to optimize the β-carboline series against human MAO-A in order to explore this pocket. Therefore, a series of β-carboline derivatives has been synthesized. The compounds were evaluated for their human monoamine oxidase A and B inhibitory potency and their K(i) values were estimated. The results show that O-alkylated compounds with lipophilic groups like cyclohexyl, phenyl and aliphatic chains increase the inhibition of MAO-A compared to harmine. Compound 3e, with the trifluorobutyloxy group, was the most active of this series, with a K(i) against MAO-A of 3.6nM. Molecular docking studies show that the trifluorobutyloxy chain occupies the hydrophobic pocket vacant with harmine. The O-alkylated compounds are less active on MAO-B than on MAO-A. However, several compounds show a better inhibition on MAO-B compared to harmine. Compound 3f, with the cyclohexylmethoxy chain, displayed the best inhibitory activity against MAO-B with a K(i) value of 221.6nM. This cyclohexyl bearing analogue is also a potent MAO-A inhibitor with a K(i) value of 4.3nM. Molecular docking studies show that the cyclohexyl chain also occupies a hydrophobic pocket but in different ways in MAO-A or MAO-B.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21183355     DOI: 10.1016/j.bmc.2010.11.041

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  22 in total

1.  Targeting imidazoline site on monoamine oxidase B through molecular docking simulations.

Authors:  Fernanda Pretto Moraes; Walter Filgueira de Azevedo
Journal:  J Mol Model       Date:  2012-03-17       Impact factor: 1.810

Review 2.  Neurotrophic function of phytochemicals for neuroprotection in aging and neurodegenerative disorders: modulation of intracellular signaling and gene expression.

Authors:  Makoto Naoi; Keiko Inaba-Hasegawa; Masayo Shamoto-Nagai; Wakako Maruyama
Journal:  J Neural Transm (Vienna)       Date:  2017-10-13       Impact factor: 3.575

3.  Isoform selectivity of harmine-conjugated 1,2,3-triazoles against human monoamine oxidase.

Authors:  Saqlain Haider; Manal Alhusban; Narayan D Chaurasiya; Babu L Tekwani; Amar G Chittiboyina; Ikhlas A Khan
Journal:  Future Med Chem       Date:  2018-05-23       Impact factor: 3.808

4.  Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.

Authors:  Mir Mohammad Shahroz; Hemant Kumar Sharma; Abdulmalik S A Altamimi; Mubarak A Alamri; Abuzer Ali; Amena Ali; Safar Alqahtani; Ali Altharawi; Alhumaidi B Alabbas; Manal A Alossaimi; Yassine Riadi; Ahmad Firoz; Obaid Afzal
Journal:  Molecules       Date:  2022-02-09       Impact factor: 4.411

Review 5.  Selective MAO-B inhibitors: a lesson from natural products.

Authors:  Simone Carradori; Melissa D'Ascenzio; Paola Chimenti; Daniela Secci; Adriana Bolasco
Journal:  Mol Divers       Date:  2013-11-12       Impact factor: 2.943

Review 6.  Novel factors modulating human β-cell proliferation.

Authors:  J Shirakawa; R N Kulkarni
Journal:  Diabetes Obes Metab       Date:  2016-09       Impact factor: 6.577

Review 7.  Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

Authors:  Breland Smith; Federico Medda; Vijay Gokhale; Travis Dunckley; Christopher Hulme
Journal:  ACS Chem Neurosci       Date:  2012-08-28       Impact factor: 4.418

8.  Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.

Authors:  Michael Tarpley; Helen O Oladapo; Dillon Strepay; Thomas B Caligan; Lhoucine Chdid; Hassan Shehata; Jose R Roques; Rhashad Thomas; Christopher P Laudeman; Rob U Onyenwoke; David B Darr; Kevin P Williams
Journal:  Eur J Pharm Sci       Date:  2021-03-27       Impact factor: 5.112

9.  Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.

Authors:  Kunal Kumar; Peng Wang; Jessica Wilson; Viktor Zlatanic; Cecilia Berrouet; Susmita Khamrui; Cody Secor; Ethan A Swartz; Michael Lazarus; Roberto Sanchez; Andrew F Stewart; Adolfo Garcia-Ocana; Robert J DeVita
Journal:  J Med Chem       Date:  2020-02-19       Impact factor: 7.446

10.  In vitro evaluation of β-carboline alkaloids as potential anti-Toxoplasma agents.

Authors:  Maria L Alomar; Federico A O Rasse-Suriani; Agustina Ganuza; Verónica M Cóceres; Franco M Cabrerizo; Sergio O Angel
Journal:  BMC Res Notes       Date:  2013-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.